Dynavax Technologies Corporation(DVAX)

Description: Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

---

Keywords: Biopharmaceutical Asthma Inflammatory Diseases Hepatitis B Chronic Obstructive Pulmonary Disease Pulmonary Disease Autoimmune And Inflammatory Disease Tlr9 Treatment Of Asthma And Chronic Obstructive Pulmonary Disease Novel Products Tlr7

---

Home Page: www.dynavax.com

DVAX Technical Analysis

2100 Powell Street
EmeryVille, CA 94608
United States
Phone: 510 848 5100

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)